ClinicalTrials.Veeva

Menu

Effect of High Dose Naloxone on Secondary Hyperalgesia

Rigshospitalet logo

Rigshospitalet

Status and phase

Completed
Phase 1

Conditions

Hyperalgesia
Naloxone
Opioid Antagonist
Pain

Treatments

Drug: Naloxone (2 mg/kg)
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01935206
H-2-2012-174

Details and patient eligibility

About

Recent studies have focused on the role of endogenous opioids on central sensitization. Central sensitization is known to be impaired or altered in chronic pain conditions, as fibromyalgia or chronic tension headache.

Animal studies have shown reinstatement of mechanical hypersensitivity following naloxone administration after resolution of an injury. This suggests latent sensitization.

In the present study, investigators hypothesize that naloxone (2 mg/kg) can reinstate secondary hyperalgesia 168 hours after a first-degree burn-injury. Investigators aim therefore to show that latent sensitization is present in humans and is modulated by endogenous opioids.

Enrollment

15 patients

Sex

Male

Ages

20 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • healthy man
  • written informed consent
  • ASA 1-2
  • BMI 18 < BMI < 30
  • normal ultrasound examination of the heart
  • normal ECG
  • urin sample without traces of opioids

Exclusion criteria

  • volunteers, who do not understand the Danish language
  • participation in another experimental trial in the previous 60 days
  • nerve damage or skin lesions in the assessment areas
  • neurological or psychiatric condition
  • use of psycho-active drugs
  • abuse of alcohol or drugs
  • chronic pain
  • regular use of pain-killers (> 1 a week)
  • allergy against morphine or other opioids (including naloxone)
  • use of prescription drugs 1 week prior to the trial
  • use of over-the-counter medication 48 hours prior to the trial
  • urin sample with traces of opioids
  • volunteer is not suitable for the trial according to the investigator's consideration

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

15 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
Treatment:
Drug: Placebo
Naloxone (2 mg/kg)
Experimental group
Description:
The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
Treatment:
Drug: Naloxone (2 mg/kg)

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems